It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prisons in the United States have become a hotbed for spreading COVID-19 among incarcerated individuals. COVID-19 cases among prisoners are on the rise, with more than 143,000 confirmed cases to date. However, there is paucity of data addressing clinical outcomes and mortality in prisoners hospitalized with COVID-19. An observational study of all patients hospitalized with COVID-19 between March 10 and May 10, 2020 at two Henry Ford Health System hospitals in Michigan. Clinical outcomes were compared amongst hospitalized prisoners and non-prisoner patients. The primary outcomes were intubation rates, in-hospital mortality, and 30-day mortality. Multivariable logistic regression and Cox-regression models were used to investigate primary outcomes. Of the 706 hospitalized COVID-19 patients (mean age 66.7 ± 16.1 years, 57% males, and 44% black), 108 were prisoners and 598 were non-prisoners. Compared to non-prisoners, prisoners were more likely to present with fever, tachypnea, hypoxemia, and markedly elevated inflammatory markers. Prisoners were more commonly admitted to the intensive care unit (ICU) (26.9% vs. 18.7%), required vasopressors (24.1% vs. 9.9%), and intubated (25.0% vs. 15.2%). Prisoners had higher unadjusted inpatient mortality (29.6% vs. 20.1%) and 30-day mortality (34.3% vs. 24.6%). In the adjusted models, prisoner status was associated with higher in-hospital death (odds ratio, 2.32; 95% confidence interval (CI), 1.33 to 4.05) and 30-day mortality (hazard ratio, 2.00; 95% CI, 1.33 to 3.00). In this cohort of hospitalized COVID-19 patients, prisoner status was associated with more severe clinical presentation, higher rates of ICU admissions, vasopressors requirement, intubation, in-hospital mortality, and 30-day mortality.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Henry Ford Health System, Department of Internal Medicine, Henry Ford Allegiance Hospital, Jackson, USA (GRID:grid.239864.2) (ISNI:0000 0000 8523 7701); Harvard University, Harvard T.H. Chan School of Public Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Henry Ford Hospital, Department of Internal Medicine, Division of Infectious Diseases, Detroit and West Bloomfield, USA (GRID:grid.413103.4) (ISNI:0000 0001 2160 8953)
3 Henry Ford Health System, Department of Internal Medicine, Henry Ford Allegiance Hospital, Jackson, USA (GRID:grid.239864.2) (ISNI:0000 0000 8523 7701)
4 Henry Ford West Bloomfield, Division of Hospital Medicine, West Bloomfield, USA (GRID:grid.239864.2)
5 Michigan State University College of Osteopathic Medicine, Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2150 1785)
6 Oregon Health and Science University, Knight Cardiovascular Institute, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)




